Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat Combined With Fuzuloparib in Advanced or Recurrent Ovarian Epithelial Carcinoma
NCT07339553Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat in ovarian epithelial carcinoma, sponsored by Peking University Third Hospital. Primary endpoint: Objective Response Rate at 12 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
ovarian epithelial carcinoma
Beyond the preview
Go deeper on NCT07339553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339553.